Hangzhou Tigermed Consulting Co., Ltd (SHE:300347)

China · Delayed Price · Currency is CNY

56.04

+0.61 (1.10%)

Apr 8, 2026, 3:04 PM CST

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Clinical trial technical services	3.27B	3.18B	4.17B	4.13B	2.99B
Clinical trial technical services Growth	2.79%	-23.75%	1.04%	37.80%	-
Clinical trial related services and laboratory services	3.45B	3.30B	3.12B	2.88B	2.19B
Clinical trial related services and laboratory services Growth	4.57%	5.61%	8.51%	31.12%	-
Unallocated Other	119.47M	129.04M	94.93M	83.93M	26.17M
Unallocated Other Growth	-7.41%	35.93%	13.10%	220.69%	-
Total	6.83B	6.60B	7.38B	7.09B	5.21B
Total Growth	3.48%	-10.58%	4.21%	35.91%	63.32%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
China	3.71B	3.55B	4.23B	3.60B	2.76B
China Growth	4.43%	-16.21%	17.57%	30.68%	44.55%
Overseas	3.13B	3.06B	3.15B	3.48B	2.46B
Overseas Growth	2.37%	-3.00%	-9.60%	41.77%	91.16%
Total	6.83B	6.60B	7.38B	7.09B	5.21B
Total Growth	3.48%	-10.58%	4.21%	35.91%	63.32%

Source: S&P Global Market Intelligence.